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ABSTRACT
Background: At present, it is difficult to predict which patients with ductal 
carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer 
(IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both 
expressed in DCIS. This study was aimed at determining whether expression of these 
antigens was related to the later development of IDC.
Results: 14 of 42 (33%) of patients developed invasive breast cancer during the 
follow up period. Only one of those DCIS cases that relapsed was positive for NYESO-1 
at diagnosis. In contrast, DCIS samples of 15 of the 28 (54%) of those patients who 
remained disease-free expressed NY-ESO-1. (Permutation chi square p=0.0033).
Methods: We identified 42 patients with DCIS, and followed them up for more 
than 10 years. NY-ESO-1 and MAGEA were demonstrated by immunostaining as were 
CD8+ infiltrates on all sections together with the conventional markers, ER, PR, and 
HER2.
Conclusions: Expression of NY-ESO-1 may predict those patients who will not 
subsequently develop invasive breast cancer and could therefore potentially be helpful 
in defining prognosis in patients with DCIS.
INTRODUCTION
Mammographic screening of healthy women has 
resulted in the increased detection of ductal carcinoma 
in Situ (DCIS), such that one-fifth of all screen detected 
breast cancers are now so diagnosed [1]. Thus, the 
incidence has more than quadrupled in women of 
screening age in the Western World. Many studies have 
attempted to determine prognostic indices that could 
assist clinicians in their decision-making. To date, nuclear 
grade and activity, comedo necrosis and HER-2 positivity 
are the prognostic signs frequently used in helping to 
decide whether conservative surgery or mastectomy is the 
preferred surgical treatment, and whether post-operative 
treatment should be administered [2, 3].
Cancer Testis (CT) genes are not normally expressed 
in adult tissues but are expressed in the human germ 
line and are activated in various malignancies. Because 
of their restricted expression pattern, CT proteins are 
frequently immunogenic in cancer patients and therefore 
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they are considered important targets for anticancer 
immunotherapy [4]. Using publicly available gene 
expression datasets to interrogate the expression of CT 
genes in breast tumors, we have demonstrated that while a 
minority of unselected breast cancers expressed CT genes, 
a significantly higher expression frequency was detected 
in estrogen (ER) and progesterone receptor (PR) negative 
breast cancer cell lines and primary breast carcinomas [5]. 
Immunohistochemical studies confirmed the association of 
CT antigen expression and ER negativity in breast tumors 
and demonstrated their frequent expression in tumors with 
higher nuclear grade [6, 7].
Recently our group has explored the expression 
of CT antigens in DCIS. We found that many 
samples of DCIS expressed a variety of CT antigens; 
amongst those for which antibodies were available for 
immunohistochemistry, we found that NY-ESO-1 was 
expressed in a high proportion of DCIS tissues, especially 
those that were ER negative [8].
This paper describes the extension to this 
study. Employing an independent set of patients with 
a documented follow-up period, we have explored 
the relationship between NY-ESO-1 expression and 
subsequent development of invasive breast cancer. The 
data show that lack of NY-ESO-1 expression confers a 
higher risk of developing invasive breast cancer in this 
cohort of patients.
RESULTS
Univariate characteristics
Patients were followed up for a mean of 10.54 years 
(Table 1). 12/42 (29%) patients had histologically assessed 
high-grade DCIS, with the remaining patients having 
intermediate or low-grade DCIS. The majority of patients 
(86%) received radiotherapy after surgery. No patient 
received systemic therapy after excision of DCIS.
NY-ESO-1 and MAGEA were expressed in 38% and 
17% of cases, respectively. Positive staining was where 
all or a plurality of the tumour cells were stained. CD8+ 
lymphocytes were detected in 96% of cases and were 
classified into three grades as previously described [8] 
(Table 2). We found positive results for ER, PR and HER2 
in 60%, 50% and 19% of the cases, respectively.
Univariate associations to invasive disease
During the follow-up period, 14 of 42 (33%) 
patients developed IDC: only 1 case of those DCIS cases 
that relapsed was positive for NY-ESO-1 at diagnosis 
(Table 3). In contrast, DCIS samples of 15 of the 28 (54%) 
of those patients who remain disease-free expressed NY-
ESO-1 (permutation chi square p=0.0033). Expression of 
NY-ESO-1 was significantly associated with 94% lower 
odds of having invasive disease (Table 3). In contrast 
to the good predictive effect of NYESO- 1, MAGEA 
expression appeared to correlate with subsequent IDC 
development. The presence of CD8+ lymphocytes was not 
predictive of development of invasive disease.
Kaplan-Meier plots were constructed for all 
markers under study. Only NY-ESO-1 and MAGEA had 
a significant likelihood ratio test (LRT) p-value at 0.0262 
and 0.0383 respectively to predict better outcome in the 
case of NY-ESO-1 and worse outcome in the case of 
MAGEA (Table 3 and Figure 1).
Association between the markers
There was no relationship between NY-ESO-1 and 
MAGEA expression, nor between NY-ESO-1 and presence 
of CD8+ lymphocytes; a weak relationship was found 
between MAGEA and CD8 (p value<0.05) (Additional 
file 1: Supplementary Table 1). ER, PR and HER-2 
were also analysed but were not helpful in predicting 
recurrence (Table 4). Radiotherapy was not associated 
with development of invasive disease or with NY-ESO-1 
expression, so was not considered a true confounder of 
the aforementioned association (Supplementary Table 2).
DISCUSSION
At present it is difficult to predict which cases 
of DCIS will recur. There have been several studies 
suggesting that HER2, p16, COX-2 in combination 
with Ki67 and histologic appearance will give some 
prognostic information, but these tests are not sufficiently 
accurate to predict outcome of DCIS in individual cases 
[11, 12, 13].
Here, we show that expression of NY-ESO-1 
predicts those patients who will not subsequently develop 
invasive breast cancer, at least over the 10 year follow 
up period. NY-ESO-1 was shown to elicit spontaneous 
antibody and T-cell responses in a proportion of cancer 
patients whose tumours express this antigen and it 
constitutes one of the most immunogenic CT antigens 
identified so far [14].
The significant association we found between the 
expression of NY-ESO-1 and the lack of progression of 
the DCIS lesions may be due to the ability of the immune 
system to protect against cancer development by detecting 
(but not necessarily destroying) abnormal cells. NY-ESO-1 
is expressed in a minority of, mainly ER negative breast 
cancers; this observation, together with the recent reports 
that NY-ESO-1 expression confers a good prognosis 
in triple negative IDC [15] may suggest that most NY-
ESO-1 expressing breast cancer cells are indeed detected 
and removed by the immune system at an early stage in 
the cancer evolutionary process. This idea is supported by 
the fact that in most breast cancer studies of NY-ESO-1 
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and TILs, a heavy TIL cell infiltrate usually is seen in NY-
ESO-1 expressing cancers [16].
Those cells that remain and express NY-ESO-1 may 
be thought of as being of little risk to the patient by the 
immune system; thus, the good prognosis associated with 
NY-ESO-1 expression may be a reflection of its expression 
in cells that do not also effect a ‘danger’ signal. This would 
explain the lack of association with CD8 positive cells, 
unlike the situation in IDC, where CT antigen expression 
often correlates with CD8 TIL infiltration [15, 16].
The function of NY-ESO-1 in cellular biology 
remains to be established, but there are data that suggest 
that MAGE may be an oncogene [17]. Interestingly in the 
present work expression of MAGEA shows a correlation 
with worse prognosis (Figure 1). MAGEA has also been 
studied extensively in IDC; the consensus is that it does 
not correlate with either survival or other breast cancer 
markers such as ER, PR, or HER2 [15]. Here we found 
that there was an association between MAGEA and HER2; 
the numbers are relatively small, however, and these 
markers should be examined in a much larger series of 
cases.
We analysed tumour grade, HER2, as well as ER 
in this series, but in view of the relatively small number 
of cases, we are at this point unable to determine whether 
the addition of these markers will add anything to the 
development of a prognostic score. A further, larger study 
will be needed to address this point.
Current breast cancer screening programmes have 
resulted in a great increase in the number of DCIS cases 
diagnosed: thus, many patients are undergoing breast 
surgery that, in some cases may not be warranted. Future 
studies will show whether CT antigen expression, perhaps 
in combination with other markers, can help predict which 
patients will ultimately develop breast cancer, and who 
therefore need potentially disfiguring surgery.
Table 1: Demographic characteristics
Demographic characteristics (N=42) N (%) or Mean (SD)
Follow up time (years)
Mean (SD) 10.54 (5.29)
Recurrence time (years)
Mean (SD) 10.56 (5.32)
Death time (years)
Mean (SD) 12.70 (4.29)
Age
Mean (SD) 73.96 (8.0)
Invasive disease/Recurrence
No 28 (67%)
Yes 14 (33%)
Death
No 29 (69%)
Yes 13 (31%)
DCIS type
High grade 12 (29%)
Intermediate grade 11 (26%)
Low grade 16 (38%)
Missing 3 (7%)
Radiotherapy
No 6 (14%)
Yes 36 (86%)
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Table 2: Marker characteristics
Marker characteristics (N=42) N (%)
NY-ESO-1_E978
Negative 25 (60%)
Positive 16 (38%)
Missing* 1 (2%)
MAGEA_6C1
Negative 34 (81%)
Positive 7 (17%)
Missing * 1 (2%)
CD8
1+ 18 (43%)
2+ 9 (21%)
3+ 13 (31%)
Negative 1 (2%)
Missing* 1 (2%)
CD8 recoded
Negative or 1+ 19 (45%)
2+ or 3+ 22 (52%)
Missing* 1 (2%)
ER positive
No 11 (26%)
Yes 25 (60%)
Missing** 6 (14%)
PgR positive
No 15 (36%)
Yes 21 (50%)
Missing** 6 (14%)
Her2 positive
No 25 (60%)
Yes 8 (19%)
Missing** 9 (21%)
*material detached at staining.
**no tumour found on recutting the sections.
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Table 3: Table of markers by Recurrence/Invasive disease
Marker 
characteristics 
(N=42)
Recurrence/
Invasive disease
P-value* OR** 95% CI** P-value** HR***
95% 
CI*** P-value***
Logrank 
P-valueNo 
(n=28)
Yes 
(n=14)
NY-ESO-1_E978
Negative (n=25) 12 13 0.0033 0.061 (0.003, 0.376) 0.0118 0.138
(0.018, 
1.065) 0.0575 0.0262
Positive (n=16) 15 1
Missing (n=1) 1 0
MAGEA_6C1
Negative (n=34) 24 10 0.0772 3.2001 (0.602, 18.89) 0.172 3.2776
(0.998, 
10.76) 0.0503 0.0383
Positive (n=7) 3 4
Missing (n=1) 1 0
CD8
1+ (n=18) 11 7 0.8056 1.0526 (0.511, 2.162) 0.887 1.171
(0.669, 
2.051) 0.579 0.717
2+ (n=9) 7 2
3+ (n=13) 8 5
Negative (n=1) 1 0
Missing (n=1) 1 0
CD8 recoded
Negative or 1+ 
(n=19) 12 7 0.5067 0.8
(0.215, 
2.950) 0.735 1.053
(0.368, 
3.013) 0.923 0.923
2+ or 3+ (n=22) 15 7
Missing (n=1) 1 0
ER positive
No (n=11) 8 3 0.6848 1.037 (0.220, 5.766) 0.964 1.071
(0.276, 
4.157) 0.922 0.922
Yes (n=25) 18 7
Missing (n=6) 2 4
PgR positive
No (n=15) 9 6 0.1465 0.353 (0.073, 1.550) 0.174 0.4605
(0.130, 
1.636) 0.231 0.219
Yes (n=21) 17 4
Missing (n=6) 2 4
Her2 positive
No (n=25) 19 6 0.0739 3.1667 (0.590, 17.69) 0.174 2.5134
(0.705, 
8.966) 0.156 0.142
Yes (n=8) 4 4
Missing (n=9) 5 4
* P-values were computed using a permutation chi square test using 10,000 permutations.
**Univariate logistic regression was used to derive these values.
^^ As continuous variable.
***Univariate cox proportional hazards regression was used to derive these values.
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Figure 1: Kaplan Meier plot of probability of recurrence by NY-ESO-1 and by MAGEA status.
Table 4: Markers by ER/PGR/HER2 status
Marker 
characteristics 
(N=42)
ER positive
P-value*
PGR positive
P-value*
HER2 positive
P-value*No 
(n=11)
Yes 
(n=25)
Missing 
(n=6)
No 
(n=15)
Yes 
(n=21)
Missing 
(n=6)
No 
(n=25)
Yes 
(n=8)
Missing 
(n=9)
NY-ESO-1
Negative (n=25) 7 14 4 0.4658 10 11 4 0.3153 14 6 5 0.2151
Positive (n=16) 4 11 1 5 10 1 11 2 3
Missing (n=1) 0 0 1 0 0 1 0 0 1
MAGEA
Negative (n=34) 7 21 6 0.1569 9 19 6 0.0261 22 3 9 0.0019
Positive (n=7) 3 4 0 5 2 0 3 4 0
Missing (n=1) 1 0 0 1 0 0 0 1 0
CD8
1+ (n=18) 2 10 6 0.46 3 9 6 0.0858 11 1 6 0.0246
2+ (n=9) 3 6 0 3 6 0 8 1 0
3+ (n=13) 6 7 0 9 4 0 5 6 2
Negative (n=1) 0 1 0 0 1 0 1 0 0
Missing (n=1) 0 1 0 0 1 0 0 0 1
CD8 recoded
Negative or 1+ 
(n=19) 2 11 6 0.06 3 10 6 0.03 12 1 6 0.03
2+ or 3+ (n=22) 9 13 0 12 10 0 13 7 2
Missing (n=1) 0 1 0 0 1 0 0 0 1
*P-values were computed using a permutation chi square test using 10,000 permutations with missing values excluded.
Oncoscience39www.impactjournals.com/oncoscience
MATERIALS AND METHODS
Patients and samples
We systematically examined the cases of DCIS 
diagnosed at one institution (Charing Cross Hospital, 
London) with a mean follow up time of 10.54 (SD: 
5.29) years. All cases of surgically resected DCIS during 
1992-2006 were reviewed in this study and followed-up 
for subsequent IDC development. Age matched controls 
with similar follow-up time, consisting of patients with 
DCIS who remained disease-free, were also selected. 
Clinical samples were de-identified and obtained without 
individual consent under a protocol approved by the 
Charing Cross Hospital Institutional Review Board. All 
patients were treated with wide local excision and 36/42 
(86%) patients received radiotherapy (Table 1) following 
surgery.
Histology and immunohistochemistry
Archival H and E slides of all cases were reviewed 
to ensure the diagnosis of DCIS. Several new 5 micron 
sections were then cut from paraffin embedded blocks. 
One was stained with H and E to ensure the continued 
presence of the target lesion.
NY-ESO-1 (clone E978) and MAGEA (clone 6C1) 
were detected by IHC using previously validated and 
described reagents and methods [9, 10] Infiltrating CD8+ 
cells were demonstrated by IHC using C8/144B antibody 
as previously described [8]. Repeat immunostaining 
for ER, PR and HER2 was carried out as described 
previously [8].
Statistical analysis
Descriptive statistics were conducted for all 
demographic and other study variables and included mean 
and ± standard deviation (SD) for continuous variables 
and count and percentages for categorical ones. Univariate 
statistics were performed comparing marker variables to 
Invasive Breast Cancer, to ER/PgR and HER2 status and 
to each other using a permutation chi square test with 
10,000 permutations. Furthermore, univariate logistic 
regression models were first used to estimate the effect of 
each marker on the risk of development of Invasive Breast 
Cancer using recurrence as a categorical variable and then 
univariate cox proportional hazards regression were used 
incorporating time to recurrence to estimate probability of 
recurrence by marker status.
Descriptive Kaplan Meier curves were also used 
with the Log-rank test (LRT) comparing the survival 
distributions, with results shown in the figure heading 
and in (Supplementary Table 1). Potential confounding 
by DCIS type, age and radiotherapy was also assessed 
for each of the markers using a permutation chi square 
test or a permutation Kruskal Wallis test with 10,000 
permutations as dictated by the categorical or continuous 
nature of the variables.
CONCLUSIONS
In summary, we have found a ‘protective effect’ 
of NY-ESO-1 expression in DCIS cases that appears to 
confer, as in primary breast cancer, a good prognosis. This 
result needs to be confirmed in a much larger series of 
patients before NY-ESO-1 immunostaining could be used 
to stratify patients to assist clinical management.
Additionally, as a result of its high immunogenicity, 
NY-ESO-1 based vaccines have been tested in multiple 
trials that have demonstrated their ability of eliciting T-cell 
and antibody responses [4, 14]. Anti-cancer vaccines 
based on NY-ESO-1 may be beneficial in the management 
of DCIS patients to boost pre-existing immunity to NY-
ESO-1, which may support T cell expansion and activation 
and help overcome immunosuppressive elements within 
the tumor, resulting in improved tumour rejection.
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